Inactive Instrument

Acasti Pharma Inc Stock price Toronto S.E.

Equities

APO

CA00430K4028

Pharmaceuticals

Sales 2024 * - Sales 2025 * - Capitalization 43.43M 31.92M
Net income 2024 * -18M -13.23M Net income 2025 * -22M -16.17M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-2.39 x
P/E ratio 2025 *
-2.83 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.98%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Acasti Pharma Inc

Managers TitleAgeSince
Chief Executive Officer 52 21-07-31
Director of Finance/CFO 52 Jan. 04
Chief Tech/Sci/R&D Officer 52 23-05-07
Members of the board TitleAgeSince
Director/Board Member 57 23-10-09
Director/Board Member - 23-10-09
Director/Board Member - 23-10-09
More insiders
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
More about the company
  1. Stock
  2. Equities
  3. Stock Acasti Pharma Inc.
  4. Stock Acasti Pharma Inc - Toronto S.E.